Introduction

Mercachem provides a wide range of chemical services to the life sciences industry.
We specialise in exclusive synthetic and process chemistry services to support research and development programs of companies across the globe.

We have the equipment and knowledge necessary to carry out organic reactions ranging from milligram to 1 kilogram scale. Moreover, we offer parallel synthesis of focused libraries. Mercachem's process research services focus on the development of efficient production processes for selected candidates.

Press release:

 

Mercachem awarded Best Managed Company 2013


Nijmegen, June 3th 2013, Mercachem has again officially joined the ranks of the best-managed mid-sized companies of the Netherlands this year. Deloitte announced this last week. The qualification is part of the ‘Best Managed Companies’ program, which is organized by Deloitte in cooperation with the TiasNimbas Business School and the VNO-NCW. Deloitte concluded that the group of Best Managed Companies 2012 scored high on the theme ‘Is your comfort zone future-proof?’ Additionally, Mercachem received praise for its strategy on innovation, quality and diversified services, in combination with achieved results and outlook. (download full article in dutch) (download full article in english)

NB Health Laboratory (NBHL) and Mercachem sign an exclusive research and marketing collaboration agreement on the CK-1δ project

Sapporo, Japan and Nijmegen, the Netherlands, 31 May 2013.
NB Health Laboratory (Sapporo, Japan) and Mercachem (Nijmegen, The Netherlands) agreed to expand their relationship from a medicinal chemistry partnership to an exclusive research and marketing collaboration.
Under this agreement, Mercachem will perform a lead optimization campaign on Casein Kinase 1 delta (CK-1δ) inhibitor series of NBHL and look for novel back-up series. The highly sensitive screening facilities at NBHL and the expert knowledge of Mercachem in the kinase inhibitor field, together with its efficient (parallel) synthetic capabilities create a strong discovery platform. The goal of this collaboration is to progress a number of CK-1δ inhibitors to clinical development. This project is offered as in-licensing opportunity. (download full article)

Mercachem and ProQinase obtain € 2.5 Mio EU EUROSTARS Grant
to establish Epigenetics Drug Discovery Platform

Freiburg, Germany & Nijmegen, the Netherlands – 13 May 2013.
ProQinase and Mercachem received a € 2.5 Mio grant from the EU’s Eurostars
program to support their joint efforts in establishing and expanding an innovative
small molecule drug discovery platform. (download full article)

Mercachem BV selected as one of the partners to join the newly launched €196 million pan-European drug discovery platform

Nijmegen, 7 February 2013: The European Lead Factory, a novel platform for innovative drug discovery, was launched today by an international consortium of 30 partners. This partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates unprecedented opportunities for the discovery of new medicines by providing public partners with an ‘industry-like’ discovery platform to translate cutting-edge academic research into highquality drug lead molecules on a scale and speed that was not possible previously.
(download full article)

Mercachem is awarded Best-Managed Company 2012

Nijmegen, June 29th 2012: Mercachem has officially joined the ranks of the best-managed midsized companies of the Netherlands this year. This was announced by Deloitte last week. The qualification is part of the ‘Best Managed Companies’ program, which is organised by Deloitte in cooperation with the TiasNimbas Business School and the VNO-NCW. Deloitte concluded that the group of Best Managed Companies 2012 scored high on innovative capabilities. Additionally, Mercachem received praise for people management and its corporate culture. (download full article in dutch)
(download full article in english)

NB Health Laboratory (NBHL) and Mercachem –NBHL appoints Mercachem as medicinal chemistry partner

Sapporo, Japan and Nijmegen, the Netherlands, 21 May 2012. NBHL (Sapporo, Japan) has appointed Mercachem (Nijmegen, The Netherlands) for optimization of its inhibitor series within the CK1 Delta project. Under this agreement, NBHL will utilize the expert knowledge of Mercachem in medicinal chemistry especially in the field of kinase inhibitors, together with its efficient synthetic capabilities. The purpose of this research project is to further optimize the lead compound of NBHL towards a pre-clinical development candidate. (download full article)

Khondrion and Mercachem - industrial partners in a ZonMW PM-RARE grant focusing on developing new drugs to treat MELAS syndrome

Nijmegen, The Netherlands, 8 May 2012. A ZonMW grant of € 3.0 million has been awarded to a national consortium consisting of the Radboud University Nijmegen Medical Centre Khondrion and Mercachem, the two industrial partners, and three mitochondrial patient organizations (VSN, ESN and IMP). This grant will support an ambitious scientific and industrial collaboration to discover treatments for MELAS syndrome, a rare mitochondrial disease that affects both children and adults.
(download full artice)

Dr. August Wolff GmbH & Co. KG Arzneimittel and Mercachem update on drug development collaborations

Bielefeld, Germany & Nijmegen, the Netherlands – 14 March 2012. Dr. August Wolff GmbH & Co. KG Arzneimittel and Mercachem have reached important milestones in two drug development collaborations. In both projects in vivo proof of concept has been shown, moreover in one of them a preclinical candidate has been nominated. The development projects involve novel classes of molecules with potential use in dermatology. (download full article)

Mercachem announces appointment of Dr. Gerhard Müller as Senior Vice President Medicinal Chemistry

Nijmegen, the Netherlands - May 24, 2011. Mercachem is pleased to announce that Dr. Gerhard Müller has joined the management team of Mercachem as Senior Vice President Medicinal Chemistry thus supporting the strong growth of the medicinal chemistry services and projects. Gerhard will be responsible for expanding Mercachem’s activities in Medicinal Chemistry. (download full article)

Dr. August Wolff Arzneimittel GmbH & Co. KG and Mercachem B.V. start two drug development collaborations

Bielefeld, Germany & Nijmegen, the Netherlands – August 26, 2010. Dr. August Wolff GmbH & Co. KG Arzneimittel and Mercachem have started two multi-year drug development collaborations. Dr. August Wolff GmbH & Co. KG Arzneimittel have licensed a number of patents from universities that cover novel classes of molecules with potential use in dermatology. Mercachem is responsible for medicinal chemistry and project management with the goal to further improve the properties of these molecules and to develop them into clinical candidates. (download full article)

Entrepreneur of the year 2010 of Nijmegen city

On 18 May 2010 the founders of Mercachem have been awarded with the title "Entrepreneur of the year 2010 of Nijmegen city" as a successful example of knowledge based entrepreneurship. Mercachem is one of the leading CRO's in Europe with nearly 110 employees in the area of (medicinal) chemistry, small molecule library services and early process R&D.


Foto: Theo van Zwam